Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
12/1999
12/02/1999WO1999061006A1 Layering process and apparatus therefor
12/02/1999WO1999061004A1 Controlled release lipoic acid
12/02/1999WO1999061002A1 Enteric coated pharmaceutical composition and method of manufacturing
12/02/1999WO1999061001A1 Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
12/02/1999WO1999061000A1 Powder containing fat-soluble drug
12/02/1999WO1999060997A1 Pharmaceutical compositions comprising an amphoteric surfactant an alkoxylated cetyl alcohol and a polar drug
12/02/1999WO1999060948A2 Medium for treating eye diseases
12/02/1999WO1999060869A1 Sitostanol formulation with emulsifier to reduce cholesterol absorption
12/02/1999WO1999053958A3 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
12/02/1999WO1999052523A3 Flutamide compositions and preparations
12/02/1999WO1999051212A3 Device for the transdermal delivery of diclofenac
12/02/1999WO1999047173A3 Carrier for in vivo delivery of a therapeutic agent
12/02/1999WO1999045938B1 Thrombin preparation and products and fibrin sealant methods employing same
12/02/1999DE19821788C1 Transdermales Therapeutisches System (TTS) Pergolid enthaltend Transdermal therapeutic system (TTS) containing pergolide
12/02/1999CA2333592A1 Methods of inhibiting clot formation
12/02/1999CA2333321A1 Drug complex
12/02/1999CA2333319A1 Layering process and apparatus therefor
12/02/1999CA2333021A1 Conjugates of an amf ligand and a cytotoxic molecule for use in cancer therapy
12/02/1999CA2330611A1 Bifunctional molecules and therapies based thereon
12/02/1999CA2321927A1 Treatment of c. difficile toxin b associated conditions
12/01/1999EP0960886A1 Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
12/01/1999EP0960141A1 Cross-linked vinyl polymers with bile acid adsorbing effect
12/01/1999EP0960132A1 Polysaccharide, micro-organism and method for obtaining same, composition containing it and application
12/01/1999EP0960119A1 T cell antigen receptor peptides
12/01/1999EP0959905A2 Polysaccharide-peptide-conjugates
12/01/1999EP0959904A2 Hybrid compositions for intracellular targeting
12/01/1999EP0959891A1 Anthelmintic formulations
12/01/1999EP0959880A1 Pharmaceutical formulation
12/01/1999EP0959873A2 Gel composition and methods
12/01/1999EP0831773B1 Peptide/protein suspended formulations
12/01/1999EP0783302B1 Medicaments
12/01/1999EP0740708A4 Design of drugs involving receptor-ligand-dna interactions
12/01/1999EP0725642B1 Stabilized prostaglandin e 1
12/01/1999EP0697866B1 High dose formulations
12/01/1999EP0576612B1 Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
12/01/1999CN1237161A New amino alcohol derivatives, process for production thereof and medicaments and reagents containing these compounds
12/01/1999CN1237106A Stable medicinal compositions containing 4,5-epoxymorphinane derivatives
12/01/1999CN1237104A Fast decomposing pellets
12/01/1999CN1237091A Composition comprising liquid absorbed on support based on precipitate silica
12/01/1999CN1236648A Process for preparing compound sosoloid
12/01/1999CN1236613A Medicinal composition for preventing and curing hypokalemia.
12/01/1999CN1046852C Process for preparing microspheroidal composition for non-enterogastric area of warm blooded animal
12/01/1999CN1046851C Process for preparing solid oral forms containing isocyclo-phosphoamide as active substance
11/1999
11/30/1999US5994517 Homogeneous conjugate of carbohydrate ligand which binds to hepatic receptor, a bifunctional linker, and a biological stable oligonucleotide and derivative can be released from conjugate; for targeted antisense agents
11/30/1999US5994495 Selectively functionalizable desdendrimers
11/30/1999US5994492 Microgels
11/30/1999US5994392 Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
11/30/1999US5994341 Anti-angiogenic Compositions and methods for the treatment of arthritis
11/30/1999US5994339 Oxidant scavengers
11/30/1999US5994338 Stabilized pharmaceutical compositions, with quinupristine and dalfopristine base and their preparation
11/30/1999US5994325 Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
11/30/1999US5994318 Complex; administering biologically active material
11/30/1999US5994316 Method of preparing polynucleotide-carrier complexes for delivery to cells
11/30/1999US5994314 Compositions and methods for nucleic acid delivery to the lung
11/30/1999US5994313 Regulated apoptosis
11/30/1999US5994311 Using a oligopeptides, polypeptide
11/30/1999US5994151 Selenium-carrier conjugate comprises (i) an organic selenium compound with atleast one reactive group selected from amino, aldehyde, alcohol, phosphate, sulfate, halogen and phenol(ii) a carrier which is covelently attached with reactive group
11/30/1999US5994127 In vivo production and delivery of erythropoietin or insulinotropin for gene therapy
11/30/1999US5994109 Nucleic acid transporter system and methods of use
11/30/1999US5993972 Improved amphiphilic diol is prepared with a controlled type and amount of alkylene glycol, catalyst, hydrophobic and hydrophilic diol with diisocyanate and water.
11/30/1999US5993859 Pharmaceutical agents
11/30/1999US5993855 Microspheres prepared by emulsifying an aqueous phase containing a drug and an oil phase containing a biodegradable polylactide to form a w/o emulsion, and then mixing and agitating this emulsion with another aqueous phase to form a
11/30/1999US5993836 Topical anesthetic formulation
11/30/1999US5993828 Administering to the subject an effective dose of a composition comprising inactivated tumor cells having urinary tumor associated antigen on the cell surface and at least one tumor associated antigen
11/30/1999US5993825 Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
11/30/1999US5993816 Methods to inhibit humoral immune responses, immunoglobulin production and B cell activation with 5c8-specific antibodies
11/30/1999US5993813 Family of high affinity, modified antibodies for cancer treatment
11/30/1999US5993806 Method of stabilizing pharmaceutical preparations comprising digestive enzyme mixtures
11/30/1999US5993787 Composition base for topical therapeutic and cosmetic preparations
11/30/1999US5993776 Radiopharmaceutical compositions that include an inclusion complex of a cyclodextrin and a radio-halogenated fatty acid
11/30/1999CA2180648C Aqueous topical anti-acne compositions of low ph
11/30/1999CA2180530C Transdermal device containing polyvinylpyrrolidone as solubility enhancer
11/30/1999CA2158638C A composition and a method for tissue augmentation
11/30/1999CA2103060C Penetration-promoting substance
11/26/1999CA2272840A1 Association of a retinoid with a histidine derivative
11/25/1999WO1999060167A1 Compositions and methods for topical delivery of oligonucleotides
11/25/1999WO1999060148A2 Display of viral proteins as ligands for cell-surface receptor
11/25/1999WO1999060120A2 Soluble t cell receptor
11/25/1999WO1999060119A2 Multivalent t cell receptor complexes
11/25/1999WO1999060012A1 Compositions and methods for non-parenteral delivery of oligonucleotides
11/25/1999WO1999059643A2 Liposomal delivery complex
11/25/1999WO1999059639A1 Solid preparations for oral administration of drugs relating to genes
11/25/1999WO1999059638A2 Compositions and methods for the delivery of nucleic acid molecules
11/25/1999WO1999059633A1 Therapeutics using a bispecific anti-hla class ii invariant chain x anti-pathogen antibody
11/25/1999WO1999059631A1 Prevention and treatment of hypergastrinemia
11/25/1999WO1999059616A1 Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives
11/25/1999WO1999059615A1 Hybrid polypeptides with enhanced pharmacokinetic properties
11/25/1999WO1999059605A1 Use of crataegus formulations for prophylaxis and treatment of neoplastic diseases
11/25/1999WO1999059603A1 Remedies for joint diseases bound to hyaluronic acid
11/25/1999WO1999059602A1 Novel pharmaceutical composition for use in emergency treatment and preparation method thereof
11/25/1999WO1999059601A1 Use of a nucleic acid-binding chemotherapeutic agent, and a pharmaceutical composition
11/25/1999WO1999059599A1 Edelfosin for the treatment of brain tumours
11/25/1999WO1999059598A1 Use of tricyclic antidepressants for local analgesia
11/25/1999WO1999059588A1 Medicinal composition reduced in bitterness
11/25/1999WO1999059577A1 Topical application of muscarinic analgesic drugs such as neostigmine
11/25/1999WO1999059575A1 Compositions comprising organic mono- or dinitrate for treating impotence
11/25/1999WO1999059573A1 Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
11/25/1999WO1999059572A1 Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
11/25/1999WO1999059571A1 Use of amyloid inhibitors for modulating neuronal cell death
11/25/1999WO1999059558A1 Transdermal therapeutic system containing pergolide
1 ... 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 ... 1712